Manager I, R2R Operations at Bristol-Myers Squibb

Hyderabad, Telangana, India

Apply Now

Not SpecifiedCompensation

Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

Exceptional expertise in record-to-report (R2R) accounting processes
Deep understanding of the business landscape, market trends, and industry dynamics
Open communication and cooperation skills to ensure seamless execution of R2R activities
Excellent leadership skills to inspire and motivate team members
Minimum of 5-7 years of experience (qualified candidates) or 8+ years (non CA/CMA)
Based in BMS’s Hyderabad location (expected 50% in-person)

Responsibilities

Perform R2R period-end close activities (e.g., account reconciliation QC, accounts receivable, accruals, operational reporting) and reconciliation activities
Monitor and manage specific month-end, quarter-end, and year-end related activities per close timetable in collaboration with local markets and third-party service provider
Prepare scheduled balance sheet control reconciliations
Monitor and manage internal customer satisfaction levels, taking immediate action as appropriate
Complete period audits, management level reporting, and disaster recovery related activities
Execute ad-hoc projects initiated by R2R leadership
Hold self and others to timelines, quality, and accuracy
Articulate material risks and opportunities and take an active role in designing and executing response or contingency plans

Skills

Record-to-Report

R2R Accounting

Finance

Leadership

Controllership

Accounting Processes

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free